Pekin Hardy Strauss Inc. Acquires 1,029 Shares of Humana Inc. (NYSE:HUM)

Pekin Hardy Strauss Inc. raised its holdings in Humana Inc. (NYSE:HUM) by 3.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 31,849 shares of the insurance provider’s stock after acquiring an additional 1,029 shares during the period. Humana comprises approximately 1.3% of Pekin Hardy Strauss Inc.’s holdings, making the stock its 9th biggest position. Pekin Hardy Strauss Inc.’s holdings in Humana were worth $10,088,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. Advisors Asset Management Inc. raised its position in Humana by 4.5% during the 1st quarter. Advisors Asset Management Inc. now owns 5,370 shares of the insurance provider’s stock worth $1,862,000 after purchasing an additional 230 shares during the last quarter. Khrom Capital Management LLC increased its stake in shares of Humana by 77.9% in the first quarter. Khrom Capital Management LLC now owns 113,195 shares of the insurance provider’s stock valued at $39,247,000 after buying an additional 49,549 shares during the period. Kingdon Capital Management L.L.C. bought a new position in shares of Humana during the first quarter worth about $20,456,000. Janus Henderson Group PLC lifted its stake in shares of Humana by 47.4% in the first quarter. Janus Henderson Group PLC now owns 975,097 shares of the insurance provider’s stock worth $338,026,000 after acquiring an additional 313,530 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Humana by 15.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 540,978 shares of the insurance provider’s stock valued at $187,568,000 after acquiring an additional 72,511 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of HUM opened at $298.11 on Friday. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $527.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a 50 day moving average price of $276.83 and a two-hundred day moving average price of $330.68. The firm has a market capitalization of $35.90 billion, a P/E ratio of 26.40, a P/E/G ratio of 2.33 and a beta of 0.52.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts forecast that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is 31.36%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HUM. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a report on Thursday, October 3rd. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. TD Cowen upped their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. boosted their price objective on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.